Collegium Pharmaceutical, Inc. has announced impressive financial results for the third quarter of 2026, showcasing a significant increase in revenue and growth in its ADHD product line. The company reported a record quarterly net revenue of $216.3 million, marking a 3% increase year-over-year. This strong performance is particularly driven by the success of its ADHD portfolio, including the JORNAY PM and AZSTARYS products.

On November 5, 2026, Collegium released its earnings report, emphasizing the positive trajectory of its business. According to Vikram Karnani, President and CEO, the company saw strong demand for its ADHD products, particularly as the back-to-school season approached. "JORNAY PM reached record revenues, prescriptions, and prescriber adoption, with quarterly net revenue growing 24% year-over-year," Karnani stated.

Collegium Pharmaceutical, headquartered in Stoughton, Massachusetts, operates within the pharmaceutical preparations industry, classified under SIC code 2834. The company trades on the Nasdaq under the ticker symbol COLL. Its recent filings include a 10-Q for the quarter ended September 30, 2026, and the current 8-K detailing the latest financial results, which was filed on the same date.

The filing indicates that Collegium generated a record $51.9 million in net revenue from JORNAY PM, a 24% increase compared to the same quarter last year. Additionally, the company reported $26.5 million in net revenue from AZSTARYS, marking its first full quarter of sales since Collegium acquired the product. This acquisition has proven beneficial, as AZSTARYS prescriptions grew nearly 2% year-over-year.

Colleen Tupper, Chief Financial Officer, highlighted the company's financial health, stating, "We generated a record $216.3 million in quarterly net revenue and $121.6 million in adjusted EBITDA, with our ADHD franchise now contributing more than 36% of total revenue." The company reaffirmed its full-year 2026 financial guidance, emphasizing a disciplined approach to capital allocation, including paying down debt and returning capital to shareholders.

The results from Collegium may have implications for various stakeholders, including investors, healthcare providers, and patients. The continued growth in the ADHD product line demonstrates the company's ability to meet market demands effectively while expanding its reach within the pharmaceutical sector.

Looking ahead, Collegium is expected to continue its momentum, with plans to complete a previously announced $50 million accelerated share repurchase program before the end of the year. This move is indicative of the company's confidence in its long-term growth prospects.

Overall, Collegium Pharmaceutical's robust Q3 results reflect a strong performance in the competitive pharmaceutical preparations industry, positioning the company well for future growth and success.